Table 2 Prevalence of HPV groups in clinician- and self-collected specimens (n = 406)
| Â | Prevalence | Concordance | ||||||
|---|---|---|---|---|---|---|---|---|
| Â | Clinician-collected | Self-collected | Â | % Positive agreement | Â | Â | ||
| Â | Prevalence | 95% CI | Prevalence | 95% CI | % Agreement | Kappa | p | |
Any HPV | 42.4% | 37.5%-47.3% | 54.7% | 49.7%-59.6% | 73% | 57% | 0.48 | <0.001 |
Carcinogenic | 18.0% | 14.4%-22.1% | 26.8% | 22.6%-31.4% | 84% | 47% | 0.54 | <0.001 |
Non-Carcinogenic | 31.8% | 27.3%-36.5% | 44.6% | 39.7%-49.6% | 75% | 53% | 0.49 | <0.001 |
alpha 1/8/10 | 3.2% | 1.7%-5.4% | 5.2% | 3.2%-7.8% | 97% | 42% | 0.57 | 0.06 |
alpha 5/6/9/11 | 28.8% | 24.5%-33.% | 41.4% | 36.5%-46.4% | 77% | 51% | 0.51 | <0.001 |
alpha 3/4/15 | 21.2% | 17.3%-25.5% | 31.8% | 27.3%-36.5% | 82% | 48% | 0.53 | <0.001 |